All articles tagged: Malignant melanoma of right lower limb, including hip (C43.71)

The FDA approves a groundbreaking treatment for advanced melanoma, offering hope to patients. The therapy involves a combination of drugs targeting specific genetic mutations in the cancer cells. This approval marks a significant advancement in melanoma treatment options.

For patients with advanced melanoma, early 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging can identify metabolic changes that may predict response to pembrolizumab, according to a study published online Jan. 24 in Clinical Cancer Research.Thomas M. Anderson, M.D., from the Per

Individuals with recent weight loss have a significantly increased risk for cancer during the subsequent 12 months, according to a study published online in the Jan. 23/30 issue of the Journal of the American Medical Association.Qiao-Li Wang, M.D., Ph.D., from Harvard Medical School in Boston, and colleagues examined the rates of subseq

Relatives of patients with myelodysplastic neoplasia (MDS), acute myeloid leukemia (AML), or acute lymphoblastic leukemia (ALL) have an increased risk for cancer, according to a study published in the February issue of Cancer Epidemiology.Nikolaj Juul Nitschke, from Copenhagen University Hospital in Denmark, and colleagues estimated t

The first medical device powered by artificial intelligence and designed to help doctors catch skin cancer has been approved by the U.S. Food and Drug Administration.Although not meant to be used as a primary screening tool, the technology further evaluates skin lesions that doctors have already flagged as suspicious, the FDA noted in an agenc

Initiation of immunotherapy for metastatic cancer at the end of life (EOL) is increasing over time, according to a study published online Jan. 4 in JAMA Oncology.Daniel M. Kerekes, M.D., from Yale University in New Haven, Connecticut, and colleagues examined patient characteristics, practice patterns, and risk factors concerning

Moderna and Merck are teaming up to create an mRNA-based melanoma vaccine, a promising development in melanoma treatment. This collaborative effort leverages cutting-edge immunotherapy to potentially offer a highly effective and minimally invasive solution for patients with skin cancer.

In a recent trial, a new melanoma vaccine, mRNA-4157 (V940), when taken in combination with Keytruda (pembrolizumab), was found to be effective in battling the deadly skin cancer.People with advanced melanomas who received the vaccine plus Merck's cancer drug Keytruda were 49 percent less likely to die or have their cancer return after three yea